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Abstract
Purpose: Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development 
and progression of solid tumors. A 936C  T polymorphism in the VEGF gene has been associated with reduced VEGF plasma levels. 
Purpose of the present study was to analyze the potential association between VEGF genotype and radiological appearance of breast 
lesions by mammography.
Materials and Methods: Fifty two women with 54 suspected breast lesions were analyzed by the use of mammography with the standard 
breast imaging reporting and data systems (BI-RADS). Germline VEGF genotype was determined in all subjects by allele-specific 
digestion of amplification products. An open biopsy was performed on all lesions.
Results: VEGF CC, CT and TT genotypes were found in 41 (79%), 9 (17%) and 2 (4%) patients. By mammography 26, 16 and 
12 suspected breast lesions were classified as BI-RADS scores 3, 4 and 5, respectively. Both carriers of the TT genotype were classified 
as BI-RADS 5, whereas among CT or CC carriers, BI-RADS scores 3, 4 and 5 were found in 26, 16 and 10 subjects (P  0.026).
Conclusion: The VEGF 936C  T polymorphism seems to be associated with a high BI-RADS score in women with suspicious breast 
lesions.
Keywords: vascular endothelial growth factor, VEGF, breast cancer, polymorphismWehrschuetz et al
78  Breast Cancer: Basic and Clinical Research 2009:3
Introduction
Vascular  endothelial  growth  factor  (VEGF)  is  an 
important regulator of vasculogenesis and angiogenesis 
with a specific mitogenicity for endothelial cells.1,2 
In addition, VEGF can increase capillary permeability, 
dilate arteries and attract monocytes chemotactically.3,4 
VEGF  is  a  disulfide-bonded  dimeric  glycoprotein, 
sharing  close  sequence  homology  with  VEGF-B 
and VEGF-C and placenta growth factor, and lower 
sequence  homology  with  platelet-derived  growth 
factor.5,6 Strong expression of VEGF has been observed 
in a variety of tissues, including tissues of the female 
reproductive system, ischemic tissues, tumours and 
transformed cell lines.7
Breast  cancer  is  the  most  frequently  diagnosed 
cancer in Western societies, with a lifetime incidence 
of about 10%–13% among women.8,9 Mammography 
is the accepted method for screening to diagnose small 
breast cancers. The present study intended to analyze 
the  potential  association  between  VEGF  genotype 
and  the  radiological/mammographic  assessment  of 
breast lesions.
Materials and Methods
subjects
Fifty-two women (age range, 30–82; mean age, 54.5 
+/- 11.8 years) were prospectively enrolled in our trial 
between  October  2002  and  March  2003.  Inclusion 
criteria were 1) breast symptoms, 2) no history of breast 
cancer, 3) female sex, 4) written informed consent. 
Exclusion criteria were 1) history of breast cancer, 2) 
pregnancy and 3) age under 18 years. All women had a 
full diagnostic work up including clinical examination, 
mammography,  breast  ultrasound  and  all  had  a 
preoperative localisation procedure under stereotactic 
or ultrasound guidance. Each woman provided a blood 
sample  preoperatively  for  further  genetic  analysis. 
Each  sample  was  marked  with  a  serial  number  to 
assure  data  protection  of  personal  data.  The  study 
was approved by the ethics committee of the Medical 
University of Graz. TNM classification, lymph node 
status, ER, PR and Her2/neu were routinely defined 
by our institute of pathology and elaborated for the 
included patients by the study authors.
statistical Analysis
P-values for the comparison of  the BI-RADS III, IV, V and 
VEGF 936C  T polymorphism and the comparison of 
VEGF 936C  T polymorphism and  TNM classification, 
lymph node status, ER, PR and Her2/neu were calculated 
with Pearson’s Chi square test and Wilcoxon-Mann-
Whitney test using the exact test option in StatXact 4.0.1 
(Cytel  Software  Corp.,  Cambridge,  MA).  Threshold 
for significance was p  0.05.
Imaging and evaluation
Mammography  was  performed  with  a  Siemens 
Mammomat 3000 (Siemens Medical System, Erlangen, 
Germany). A  dedicated Agfa  film  processor  with  an 
extended  (2-minute)  processing  cycle  was  employed 
with Adefo chemistry at 34 °C development temperature. 
A  commercial  single-emulsion  mammography  film 
with standard screens and carbon cassettes were used 
(previously MicrovisionCi, Sterling, USA—now Agfa, 
Belgium) at a mammography site approved by the Austrian 
Ministry of Public Health. Two experienced radiologists 
analyzed the mammography images. All images were 
classified by the standard breast imaging reporting 
and  data  systems  (BI-RADS).10  Breast  ultrasound 
was performed at the discretion of the radiologists 
with  a  Logiq  700  MR  (General  Electric  Medical 
System, Milwaukee, USA). A digital system (OPDIMA, 
Siemens Medical System, Erlangen, Germany) was used 
for preoperative stereotactic localisation.
A microbiologist specialised in genetics determined 
the patients’ genotypes as follow:
For genetic analyses, genomic DNA was isolated 
from venous blood by standard methods and stored at   
4 °C. A 198 bp fragment containing the polymorphic 
site was amplified by polymerase chain reaction (PCR) 
using  5´-AAGGAAGAGGAGACTCTGCGC-3´  as 
forward  and  3´-TATGTGGGTGGGTGTGTCTAC 
AGG-3´  as  reverse  primer.  The  PCR  product  was 
digested  with  restriction  endonuclease  NIaIII 
(New England Biolab); fragments were analyzed on 
2.0% agarose gels stained with ethidium bromide. The 
C allele remained uncut, while the T allele was cut 
into two fragments of 114 and 84 bp. For each set of 
reactions, a negative control containing H2O instead 
of DNA to check for contamination and a positive 
control (sample with homozygous TT genotype) to 
check for complete digestion were added.
Results
The  study  consisted  of  52  women  with  54  breast 
lesions.  VEGF  genotype  was  determined  for  all VegF 936C  T polymorphism and association of Bi-RADs score in women
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subjects. With mammography, 26, 16 and 12 suspected 
breast lesions were classified as BI-RADS category 3, 
4 and 5, respectively. VEGF CC, CT and TT genotypes 
were found in 41 (79%), 9 (17%) and 2 (4%) patients. 
The two carriers of the TT genotype were classified 
as BI-RADS 5 Figures 1 and 2; among CT or CC 
carriers, BI-RADS scores 3, 4 and 5 were found in 
26,  16  and  10  subjects,  respectively  (p    0.026) 
(Table 1). In all, 28 lesions (51.8%) were considered 
to be cancerous. No correlation was found between 
the 936C  T gene polymorphism of VEGF and tumor 
size and histological grading (p  0.83), lymph node 
status (p  0.54), estrogen receptor status (p  1.1), 
progesterone receptor status (p  0.76), or HER2/neu 
receptor status (p  0.8) (Tables 2, 3). The sensitivity 
and the specificity were 86% and 97%, respectively, 
with 92% accuracy. Histological diagnosis was the 
gold standard.
Discussion
The  aetiology  of  breast  cancer  is  still  not  fully 
understood. Besides age at menarche and menopause, 
diet, reproductive history, oestrogen administration 
and  genetic  factors  have  been  suggested  as  risk 
factors.11–15  Many  women  will  at  some  time  have 
breast symptoms, especially between 40–70 years of 
age; the risk of developing breast cancer is gradually 
increasing in this age range. During a given 10-year 
period, it is estimated that 13%–16% of women will 
seek medical advice due to breast symptoms.16,17
Our intention was to analyze the potential association 
between VEGF genotype and mammography findings 
to provide information to supplement the clinician’s 
repertoire  of  breast  palpation,  imaging  techniques, 
and biopsy.
Appropriate  management  of  breast  findings  is 
very important for the primary physician regarding a 
reported diagnosing rate for breast cancer of 4% of 
patients with breast symptoms.16 Pooled data from 
screening studies estimate sensitivity of 54%.18 There 
is considerable interobserver variability in detection 
rates  and  interpretation.  Only  25%  interobserver 
agreement was shown in a study involving experienced 
breast surgeons who evaluated breast abnormalities 
in  100  consecutive  women  with  breast  symptoms. 
Biopsy was recommended in 28%–39% of these cases, 
but only in 17% were the surgeons in agreement.19
With  breast  induration,  Kaiser  et al  found  that 
mammography  alone  had  a  sensitivity  of  60% 
for  invasive  breast  carcinoma.  The  specificity 
of  mammograms  upon  initial  imaging  was  94% 
Table  1.  Comparison  of  Bi-RADs  iii,  iV,  V  and  VegF 
936C  T polymorphism in patients with breast symptoms.
BI-RADs 
III
BI-RADs 
IV
BI-RADs 
V
Allele
  CC + CT 26 16 10
  TT 0 0 2 p  0.026
p  0.05.
Figure 1. Obscure mass due to infiltrating ductal carcinoma (pT1cN0G3) 
and branching and/or fine linear calcifications (arrow) due to infiltrating 
ductal carcinoma and ductal carcinoma in situ in the mediolateral view 
in a 47-year-old woman. BI-RADS classification V; The patient carries 
the TT allel.
Figure  2.  Branching  and/or  pleomorphic  calcifications  (arrow)  in 
mediolateral view due to ductal carcinoma in situ (pTisg2) in a 51-year-old 
woman. BI-RADS classification IV. The patient carries the CC allele.Wehrschuetz et al
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and  the  negative  predictive  value  was  97%.20 The 
usefulness of breast US in detecting carcinomas was 
demonstrated by Butler et al,21 who detected 87.7% 
of mammographically subtle or invisible lesions.
We find that it can be very difficult to evaluate 
breast symptoms by palpation, especially in patients 
who have previously undergone biopsy procedures; 
these can entail postsurgical sequelae such as breast 
scarring,  fat  necrosis,  architectural  distortion  and 
skin changes that can mislead the radiologist. We so 
hypothesized that VEGF in general and the 936C/T   
polymorphism in particular could help radiologists 
resolve these ambiguities.
In our cohort, both carriers of the TT genotype were 
classified as BI-RADS 5, whereas among CT or CC 
carriers, BI-RADS scores 3, 4 and 5 were found in 26, 
16 and 10 subjects, respectively (P  0.026). Carriers 
of the TT allele with breast symptoms thus face a 
significantly higher risk for breast cancer than those 
without that allele and, if supported by mammography 
and ultrasound, should be strongly urged to undergo 
biopsy due to their greater likelihood of having breast 
cancer  with  a  high-grade  BIRADS  than  patients 
carrying the CC or the CT allele, as suggested by the 
literature.22 Erolglu et al failed, however to find an 
association between the 936C/T polymorphism and 
clinicopathological characteristics,23 although it has 
been  demonstrated  beyond  reasonable  doubt  that 
VEGF plays an important role in breast cancer,24 and 
there appears to be a significant positive association 
between  HER-2/neu  and  VEGF  expression.25 
In any case, as our data show statistical significance 
in  the  comparison  of  936C/T  polymorphism  and 
BIRADS  scores  in  mammography,  we  propose  a 
potential  association  of  the  936C/T  polymorphism 
with mammographic appearance of breast lesions in 
women suffering breast symptoms.
A limitation of our study is its small size. Further 
prospective  trials  should  clarify  the  role  of VEGF 
and potential morphologic coherences of the VEGF 
936C    T  polymorphism  and  the  mammographic 
appearance  in  women  with  breast  symptoms,  also 
taking into account diet, hormonal status and other 
life-style  factors  that  are  known  to  contribute  to 
mammographic density.
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